Sunday, March 21, 2010 Last update: Yesterday, 10:30 PM

State-by-State AND City-by-City FreshNews.com Delivers Company Tech News

Hollis-Eden

print this company - email to a friend - join our eNewsletter

Website:

http://www.holliseden.com

News articles for Hollis-Eden:

Monday, February 2, 2009

Hollis-Eden Pharmaceuticals Announces Cost-Cutting Measures to Focus Resources on Advancement of Ongoing Clinical Development Pr

Posted at 02/02/2009 - 4:37pm

Friday, January 30, 2009

Hollis-Eden Pharmaceuticals to Present at 2009 BIO CEO and Investor Conference BIO CEO & Investor Conference 2009

Posted at 01/30/2009 - 8:43am

Monday, January 26, 2009

University of California San Diego Researchers Present Preclinical Data Demonstrating Benefits of TRIOLEX (HE3286) in Model of O

Posted at 01/26/2009 - 8:37am

Friday, January 23, 2009

Hollis-Eden Researchers Present New Findings on Mechanism of Action for Anti-Cancer Drug Candidate APOPTONE™ (HE3235) at Americ

Posted at 01/23/2009 - 10:05am

Monday, September 29, 2008

Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE (HE3235) in Preclinical Models of Castration-Resi

Posted at 09/29/2008 - 8:09am

Thursday, September 25, 2008

Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistan

Posted at 09/25/2008 - 7:53am

Friday, September 12, 2008

Hollis-Eden Pharmaceuticals Reports Update on Autoimmunity Program with TRIOLEX (HE3286) at International Autoimmunity Meeting 6

Posted at 09/12/2008 - 6:28am

Thursday, August 7, 2008

Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs

Posted at 08/07/2008 - 9:06am

Tuesday, August 5, 2008

Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with TRIOLEX (HE3286) in Rheumatoid Arthritis Patients

Posted at 08/05/2008 - 6:54am

Wednesday, July 30, 2008

Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with APOPTONE (HE3235) in Late-Stage Prostate Cancer Patients

Posted at 07/30/2008 - 6:04am

Wednesday, July 16, 2008

Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX (HE3286) in Type-2 Diabetes Patients; Expands Sites t

Posted at 07/16/2008 - 5:51am

Monday, June 9, 2008

Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with TRIOLEX Supporting Anti-Inflamm

Posted at 06/09/2008 - 6:27am

Monday, May 12, 2008

Hollis-Eden Pharmaceuticals to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference

Posted at 05/12/2008 - 6:04am

Monday, April 14, 2008

Hollis-Eden Pharmaceuticals Presents Positive Data with APOPTONE in Preclinical Bone Model of Late-Stage Prostate Cancer

Posted at 04/14/2008 - 4:13pm

Tuesday, March 18, 2008

Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with TRIOLEX in Obese Insul

Posted at 03/18/2008 - 7:47am

Tuesday, March 11, 2008

Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Fourth Quarter 2007 Financial Results and Drug Development

Posted at 03/11/2008 - 8:48am

Tuesday, February 19, 2008

Hollis-Eden Pharmaceuticals Announces Filing of IND with APOPTONE in Hormone Sensitive Cancers to Commence Phase I/II Clinical T

Posted at 02/19/2008 - 7:43am

Friday, February 8, 2008

Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial in Ulcerative Colitis with Novel Oral Anti-Inflammatory Drug Can

Posted at 02/08/2008 - 8:39am

Tuesday, February 5, 2008

Hollis-Eden Pharmaceuticals Presents Additional Data Demonstrating Activity of APOPTONE in Inducing Cancer Cell Death Findings D

Posted at 02/05/2008 - 8:50am

Monday, February 4, 2008

Hollis-Eden Pharmaceuticals to Present at 2008 BIO CEO and Investor Conference BIO CEO & Investor Conference 2008

Posted at 02/04/2008 - 8:45am

Add new comment

Biotech/Biomedical/Health